RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2020

NOTE 12: RELATED PARTY TRANSACTIONS

The following table sets forth related party transaction expenses recorded during the respective periods:


	For the Three Months Ended
	March 31,
	2020		2019
Research and development	$	235,000	$	88,500
Total	$	235,000	$	88,500

Sponsored Research Agreements with The Baylor College of Medicine (“BCM”). On November 16, 2018 and February 1, 2020, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in Sponsored Research Agreements (“SRAs”) with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM’s Center for Cell and Gene Therapy.

During the quarters ended March 31, 2020 and 2019, the Company incurred approximately $35,000 and $7,500, respectively, of expenses to BCM under the two SRAs.

Clinical Supply Agreement with BCM. On September 9, 2019, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in a Clinical Supply Agreement ("CSA") with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.

During the quarter ended March 31, 2020, the Company incurred approximately $200,000 of expenses to BCM under the CSA.

Consulting Agreement with Dr. Juan Vera. On October 19, 2018, after the closing of the Company’s merger, the Company entered into a consulting agreement with Dr. Juan Vera, a member of the Company’s board of directors, to serve as the Company’s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated.

During the quarter ended March 31, 2019, the Company incurred approximately $81,000 of expenses under Dr. Vera’s consulting agreement.